Navigation Links
Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)
Date:10/29/2008

- Management to discuss third quarter financial results -

LAVAL, QC, Oct. 29 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Friday, November 7 at 8:30 a.m. (ET) to discuss its third quarter 2008 financial results. Labopharm will report its third quarter 2008 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3427 or 1-800-588-4490. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, November 14, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21287767 followed by the number sign.

A live audio webcast of the conference call will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... 2017 , ... Loyale Healthcare today announced the ... joins other recent high-profile hires including Frank Massi, Chief Revenue Officer and Shirley ... helping physician practices and hospitals automate their clinical and financial processes to gain ...
(Date:8/23/2017)... ... , ... The Stevie® Awards have announced the winners of the Best of the IBA Awards ... competition. , Nominees in the 2017 IBAs were not able to apply for the Best ... total number of awards won in the IBAs with a Gold Stevie win counting for ...
(Date:8/23/2017)... Indiana (PRWEB) , ... August 23, 2017 , ... ... Whitney Boling, MD , has returned home to Indiana, and is now seeing ... is a board-eligible ophthalmologist that specializes in the diagnosis and treatment of eye ...
(Date:8/23/2017)... ... August 23, 2017 , ... A new literature ... Surgeons , points out that therapeutic modalities (physical therapy) is an important part ... the report, a wider scope of physical therapy options is showing promising results ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... Medicine recently spoke at a popular international aesthetics conference for medical professionals about ... restoring his patients’ health and his growing practice. , Dr. George K. ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... MJAC2017 , the premier cannabis event devoted ... reveals its leading lineup. MJAC2017 is ... innovator specializing in the development of pharmaceutical and consumer products, ... and The Green Organic Dutchman are gold sponsors for the ... sponsors. ...
(Date:8/15/2017)... POINT, N.C. , Aug. 15, 2017  Axium Pharmaceuticals Inc., the ... is rumored to be in the beginning stages of an IPO. ... annually on epilepsy medications with the average cost of a prescription epilepsy ... ... Another staggering figure is the ...
(Date:8/10/2017)... 2017  Physical Rehabilitation Network (PRN), acquired the long-standing outpatient ... Colorado . The reputable clinic will continue to be ... with his staff of four clinicians. Lipkin received his doctorate ... over 10 years of experience with a strong background in ... marks the 10th PRN clinic in and around the ...
Breaking Medicine Technology: